Extension study for HER2 amplified advanced solid tumors (JUPITER ES)

Phase 2

• Conditions: Solid tumors; HER2, solid tumor; D009369

• Registration Number: JPRN-jRCTs031220444
• Lead Sponsor: Ikeda Sadakatsu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-11-11
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

(1) Patients enrolled in the Phase II study and continuing on study treatment at the time of obtaining consent for this study.
(2) Women of child-bearing potential and partners of child-bearing potentail must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for 28 weeks following completion of study therapy.
(3) Patients signed informed consent form.

Exclusion Criteria

(1) Patients who participated in clinical studies other than the Phase II trials within 4 weeks prior to obtaining consent for this study.
(2) Patients who have a clinically significant medical condition that makes participation in this study inadvisable or makes compliance with the requirements of this study difficult.
(3) Any other patients who are regarded as inappropriate for inclusion in the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified